Get the Stockscreener App
21.33
3.92%
-0.89
Silk Road Medical Inc stock is currently priced at $21.33, with a 24-hour trading volume of 119.84K.
It has seen a -3.92% decreased in the last 24 hours and a +1.23% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $22.12 pivot point. If it approaches the $20.82 support level, significant changes may occur.
Previous Close:
$22.22
Open:
$22
24h Volume:
119.84K
Market Cap:
$846.86M
Revenue:
$177.13M
Net Income/Loss:
$-55.74M
P/E Ratio:
-15.13
EPS:
-1.41
Net Cash Flow:
$-33.52M
1W Performance:
+2.50%
1M Performance:
+1.23%
6M Performance:
+101.23%
1Y Performance:
-33.26%
1D Range:
$21.32
$22.20
52W Range:
$6.08
$34.13
Silk Road Medical Inc Stock (SILK) Company Profile
Name
Silk Road Medical Inc
Sector
Industry
Phone
408-720-9002
Address
1213 Innsbruck Drive, Sunnyvale, CA
Silk Road Medical Inc Stock (SILK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-23 | Downgrade | Argus | Buy → Hold |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Jul-12-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jul-12-23 | Downgrade | JP Morgan | Overweight → Neutral |
| May-23-23 | Initiated | CL King | Buy |
| May-15-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Apr-03-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-31-23 | Initiated | B. Riley Securities | Buy |
| Mar-10-23 | Upgrade | Citigroup | Sell → Neutral |
| Feb-07-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-22-22 | Initiated | BofA Securities | Buy |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Nov-19-21 | Upgrade | Citigroup | Sell → Neutral |
| Oct-01-21 | Downgrade | Citigroup | Neutral → Sell |
| Oct-01-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-21-20 | Initiated | Piper Sandler | Neutral |
| Jul-09-20 | Initiated | SVB Leerink | Outperform |
| May-27-20 | Initiated | Citigroup | Buy |
| Aug-20-19 | Initiated | Argus | Buy |
| Apr-29-19 | Initiated | BMO Capital Markets | Outperform |
| Apr-29-19 | Initiated | BofA/Merrill | Neutral |
| Apr-29-19 | Initiated | JP Morgan | Overweight |
| Apr-29-19 | Initiated | Stifel | Buy |
View All
Silk Road Medical Inc Stock (SILK) Latest News
A significant driver of top-line growth: Silk Road Medical Inc (SILK) – Sete News - SETE News
SETE News
Birchview Capital LP Increases Stock Holdings in Silk Road Medical, Inc (NASDAQ:SILK) - MarketBeat
MarketBeat
Birchview Capital LP Raises Holdings in Silk Road Medical, Inc (NASDAQ:SILK) - Defense World
Defense World
Bone Biologics Co. (NASDAQ:BBLGW) Short Interest Update - Defense World
Defense World
Silk Road Medical, Inc (NASDAQ:SILK) Shares Bought by Nebula Research & Development LLC - MarketBeat
MarketBeat
Silk Road Medical (NASDAQ:SILK) Trading Up 3.4% - MarketBeat
MarketBeat
Silk Road Medical Inc Stock (SILK) Financials Data
Silk Road Medical Inc (SILK) Revenue 2024
SILK reported a revenue (TTM) of $177.13 million for the quarter ending December 31, 2023, a +27.77% rise year-over-year.
Silk Road Medical Inc (SILK) Net Income 2024
SILK net income (TTM) was -$55.74 million for the quarter ending December 31, 2023, a -1.33% decrease year-over-year.
Silk Road Medical Inc (SILK) Cash Flow 2024
SILK recorded a free cash flow (TTM) of -$33.52 million for the quarter ending December 31, 2023, a +10.82% increase year-over-year.
Silk Road Medical Inc (SILK) Earnings per Share 2024
SILK earnings per share (TTM) was -$1.45 for the quarter ending December 31, 2023, a +6.45% growth year-over-year.
Silk Road Medical Inc Stock (SILK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Buchanan Lucas W. | COO/CFO |
Mar 05 '24 |
Sale |
17.17 |
9,877 |
169,578 |
500,925 |
| Davis Andrew S. | Chief Commercial Officer |
Mar 05 '24 |
Sale |
17.17 |
5,481 |
94,103 |
287,773 |
| Ruedy Richard | EVPClin&Reg.Affairs&QA |
Mar 05 '24 |
Sale |
17.17 |
3,800 |
65,242 |
205,711 |
| Jones Marie L. | VP, Finance and CAO |
Mar 05 '24 |
Sale |
17.17 |
2,602 |
44,674 |
76,894 |
| Klemz Kevin M | EVP/Chief Legal Officer/Sec. |
Mar 05 '24 |
Sale |
17.17 |
2,497 |
42,871 |
165,194 |
| Ruedy Richard | EVPClin&Reg.Affairs&QA |
Feb 29 '24 |
Sale |
22.25 |
3,000 |
66,750 |
170,837 |
| Jones Marie L. | CAO and VP, Finance |
Oct 27 '23 |
Sale |
6.61 |
656 |
4,334 |
54,941 |
| Buchanan Lucas W. | COO/CFO |
Oct 04 '23 |
Sale |
15.22 |
2,662 |
40,524 |
435,848 |
| Klemz Kevin M | EVP/Chief Legal Officer/Sec. |
Aug 17 '23 |
Sale |
20.11 |
1,539 |
30,942 |
38,797 |
| Davis Andrew S. | Chief Commercial Officer |
Aug 03 '23 |
Sale |
22.13 |
6,587 |
145,797 |
109,534 |
About Silk Road Medical Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
1.10%
0.63%
Cap:
|
Volume (24h):